Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer's
Eli Lilly $LLY had hoped that EXPEDITION3 would prove to the world that amyloid beta was the cause of Alzheimer’s and that solanezumab could bend the curve of cognitive decline back to patients’ favor — or at least for patients with an early-stage, mild form of the disease.
Instead, the landmark failure — acknowledged well over a year ago — is raising fresh questions about whether investigators have been aiming at the wrong target for more than a decade of flops and disastrous failures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
